Abstract
Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Current Drug Targets
Title:Proteomic Classification of Breast Cancer
Volume: 13 Issue: 12
Author(s): Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills and Bryan Hennessy
Affiliation:
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Abstract: Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Export Options
About this article
Cite this article as:
Kamel Dalia, Brady Bernadette, Tabchy Adel, B. Mills Gordon and Hennessy Bryan, Proteomic Classification of Breast Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530080
DOI https://dx.doi.org/10.2174/138945012803530080 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stereological Quantification of Blood and Lymph Microvessels in Prostate Cancer. Its Relevance for the Anti-angiogenetic Therapy
Current Cancer Therapy Reviews T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Pluripotent Stem Cell-Derived Somatic Stem Cells as Tool to Study the Role of MicroRNAs in Early Human Neural Development
Current Molecular Medicine RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody
Anti-Cancer Agents in Medicinal Chemistry The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Multi-Target Mining of Alzheimer Disease Proteome with Hansch’s QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline
Current Drug Targets A Novel Strategy for Preparing Glycopeptide Molecular Probe Using Fluorous Technology
Protein & Peptide Letters Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Current Topics in Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas
Anti-Cancer Agents in Medicinal Chemistry Investigation of the Antiproliferative Action of the Quinoline Alkaloids Kokusaginine and Skimmianine on Human Cell Lines
Current Signal Transduction Therapy Human-Based In Vitro Experimental Systems for the Evaluation of Human Drug Safety
Current Drug Safety Effects of Annurca Apple (Malus pumila cv Annurca) Polyphenols on Breast Cancer Cells
Current Nutrition & Food Science Efficient Green Synthesis of Bis(3-indolyl)phenylmethanes Catalyzed by 1- (Benzenesulfonyl)-3-methyl-1H-imidazolium Chlorides
Letters in Organic Chemistry <i>In vivo</i> Evaluation of [<sup>225</sup>Ac]Ac-DOTA<sup>ZOL</sup> for α-Therapy of Bone Metastases
Current Radiopharmaceuticals